Figure 5From: AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer modelsAZD8931 inhibits EGFR pathway protein expression in vivo . A. Immunohistochemical analysis of EGFR, HER2, HER3, phospho-EGFR, phospho-HER2, and phospho-HER3 in SUM149 xenografts following AZD8931 acute treatment (50 mg/kg/per day × 4 days). B. The average of pathologist’s H-score for both membrane and cytoplasmic staining.Back to article page